There isn’t any development timeline yet that one can rely on because SRDX’s in-house trials with I-vation are essentially proof-of-concept. What happens next will depend on which drug companies (if any) are interested in licensing the platform.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”